Insmed (INSM, $75.99) was one of top quarterly gainers, jumping +19 to $75.99 per share. A.I.dvisor analyzed 873 stocks in the Biotechnology Industry over the last three months, and discovered that of them (6) charted an Uptrend while of them (3) trended down.